STX.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 May 2024 @ 11:45):

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs...

Stats
Today's Volume	13.92M
Average Volume	7.42M
Market Cap	14.86M
EPS	£0 ( 2024-04-29 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.160
ATR14	£0.0310 (1.59%)

Volume Correlation

Long: -0.30 (neutral)

Short: -0.10 (neutral)

Signal:(54.378) Neutral

Shield Therapeutics PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shield Therapeutics PLC Correlation - Currency/Commodity

-0.63
( weak negative )

-0.66
( moderate negative )

0.00
( neutral )

-0.59
( weak negative )

0.58
( weak )

Shield Therapeutics PLC Financials

Annual	2022
Revenue:	£4.47M
Gross Profit:	£2.00M (44.71 %)
EPS:	£-0.170

FY	2022
Revenue:	£4.47M
Gross Profit:	£2.00M (44.71 %)
EPS:	£-0.170

FY	2021
Revenue:	£1.52M
Gross Profit:	£539 000 (35.48 %)
EPS:	£-0.165

FY	2020
Revenue:	£10.39M
Gross Profit:	£9.03M (86.96 %)
EPS:	£-0.0200

Financial Reports:

No articles found.

Shield Therapeutics PLC

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.